PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30181466-0	2018	DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways.	Doxorubicin	19-30	vitrin	Homo sapiens	4-7	
30181466-4	2018	Taken together, we synthesized DOX-Vit D by conjugating Vit-D to DOX in order to increase the delivery of DOX into cancer cells and mitigate the chemoresistance associated with DOX.	Doxorubicin	31-34	vitrin	Homo sapiens	35-38	
30181466-4	2018	Taken together, we synthesized DOX-Vit D by conjugating Vit-D to DOX in order to increase the delivery of DOX into cancer cells and mitigate the chemoresistance associated with DOX.	Doxorubicin	31-34	vitrin	Homo sapiens	56-59	
30181466-4	2018	Taken together, we synthesized DOX-Vit D by conjugating Vit-D to DOX in order to increase the delivery of DOX into cancer cells and mitigate the chemoresistance associated with DOX.	Doxorubicin	65-68	vitrin	Homo sapiens	35-38	
30181466-4	2018	Taken together, we synthesized DOX-Vit D by conjugating Vit-D to DOX in order to increase the delivery of DOX into cancer cells and mitigate the chemoresistance associated with DOX.	Doxorubicin	65-68	vitrin	Homo sapiens	35-38	
30181466-4	2018	Taken together, we synthesized DOX-Vit D by conjugating Vit-D to DOX in order to increase the delivery of DOX into cancer cells and mitigate the chemoresistance associated with DOX.	Doxorubicin	65-68	vitrin	Homo sapiens	35-38	
30181466-6	2018	Our results showed that DOX-Vit D, but not DOX, significantly elicited an apoptotic signal in MG63 cells as evidenced by induction of death receptor, Caspase-3 and BCLxs genes.	Doxorubicin	24-27	vitrin	Homo sapiens	28-31	
30181466-7	2018	Mechanistically, the DOX-Vit D-induced apoptogens were credited to the activation of p-JNK and p-p38 signaling pathway and the inhibition of proliferative proteins, p-Akt and p-mTOR.	Doxorubicin	21-24	vitrin	Homo sapiens	25-28	
30181466-9	2018	DOX-Vit D may serve as a novel drug delivery approach to potentiate the delivery of DOX into cancer cells.	Doxorubicin	0-3	vitrin	Homo sapiens	4-7	
8635156-6	1996	Vit C both at non-cytotoxic (1 microM) and moderately cytotoxic concentrations (10(2) microM) improved the cytotoxicity of DOX, DDP, and Tx significantly.	Doxorubicin	123-126	vitrin	Homo sapiens	0-3	
35241369-1	2022	PURPOSE: The primary objective of this study was to investigate the potential protective effect of Vitamin D (Vit D) on DOX induced cardio toxicity (DIC) in early breast cancer patients receiving adjuvant DOX based chemotherapy (AC).	Doxorubicin	120-123	vitrin	Homo sapiens	110-113	
35241369-1	2022	PURPOSE: The primary objective of this study was to investigate the potential protective effect of Vitamin D (Vit D) on DOX induced cardio toxicity (DIC) in early breast cancer patients receiving adjuvant DOX based chemotherapy (AC).	Doxorubicin	205-208	vitrin	Homo sapiens	110-113	
35241369-7	2022	CONCLUSION: The present work provides a promising clinical evidence to support the cardio protective effects of Vit D against DIC through attenuating the evoked pro-inflammatory cytokines induced by DOX.	Doxorubicin	199-202	vitrin	Homo sapiens	112-115